



## ***Helicobacter pylori* Infection: Therapy Changes and Challenges**

Guest Editor:

### **Dr. Chia-Jung Kuo**

1. Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
2. College of Medicine, Chang Gung University, Taoyuan, Taiwan
3. Chang Gung Microbiota Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

Deadline for manuscript submissions:

**closed (15 November 2022)**

### **Message from the Guest Editor**

Dear Colleagues,

*Helicobacter pylori* is a well-known pathogen associated with several upper gastrointestinal tract diseases, including peptic ulcer disease, atrophic gastritis, and gastric malignancies. The possible causes for eradication therapy failures include antibiotic resistance, smoking, high bacterial load before treatment, bacterial genotype, and polymorphisms of metabolism of PPIs. The successful rate of eradication of *H. pylori* has recently declined, mainly due to the increasing prevalence of drug resistance. With the changing profile of *H. pylori* antibiotic resistance, optimizing the therapy for *H. pylori* infection has become challenging.

**Keywords:** *H. pylori* infection; antibiotic resistance; multi-drug resistance; precision medicine; eradication; first-line; rescue; susceptibility test





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi